This article aims to analyse the regulatory framework of the orphan drugs for the treatment of rare diseases. After defining the concepts of “orphan drug” and “rare disease” and reviewing the U.S. and European regulatory regimes, the essay examines the Italian legislation and, in particular, the balance of the current distribution of expenditure between public bodies and private economic operators. The article reaches the conclusion that current Italian framework represents a best practice: it allows the most appropriate constitutional balance between public interest, private economic operators interest and right to health of individuals.
Orphan Drugs for the Treatment of Rare Diseases. A Comparative Public Law Perspectives / Sandulli, Aldo. - In: ITALIAN JOURNAL OF PUBLIC LAW. - ISSN 2239-8279. - XI:2(2019), pp. 476-533.
Orphan Drugs for the Treatment of Rare Diseases. A Comparative Public Law Perspectives
Aldo Sandulli
2019
Abstract
This article aims to analyse the regulatory framework of the orphan drugs for the treatment of rare diseases. After defining the concepts of “orphan drug” and “rare disease” and reviewing the U.S. and European regulatory regimes, the essay examines the Italian legislation and, in particular, the balance of the current distribution of expenditure between public bodies and private economic operators. The article reaches the conclusion that current Italian framework represents a best practice: it allows the most appropriate constitutional balance between public interest, private economic operators interest and right to health of individuals.File | Dimensione | Formato | |
---|---|---|---|
2. Sandulli.pdf
Open Access
Tipologia:
Versione dell'editore
Licenza:
DRM (Digital rights management) non definiti
Dimensione
465.68 kB
Formato
Adobe PDF
|
465.68 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.